When any medications and medicines are withdrawn from the mass market, most often people start to think that they either did not meet the initial standards of safety and effectiveness, or they have some pronounced pollutant, which disrupts the body due to intake such a drug. However, in the case of the recently recalled batches of quite popular children's cough medicines called Dimetapp and Robitussin, the situation is somewhat different – the U.S. Federal Food and Drug Administration has decided to withdraw these drugs due to the fact that their packaging does not meet certain technical requirements.
We are talking specifically about the discrepancy between the initial standards of markers and visual designation elements with those that were found on the shelves of pharmacies and stores in fact. Some time ago, the responsible team of the US FDA Federal Commission conducted a special analysis of a wide range of cough medicines and other respiratory symptoms of diseases, and found that in the case of Robitussin and Dimetapp, the main problem lies not in potential pollutants, but in the packaging lid dosage markers incorrectly indicated.
Despite the fact that both medicines are delivered to pharmacies in a fairly minimal amount of 4 and 8 ounces, this can still be enough if the parents make a mistake in the dosage – such a mistake, of course, will not cost the child health and even more so life, however, can lead to some unpleasant temporary complications that the Federal Commission and parents would surely want to avoid in the long run.
Medications of this type, which are sold literally from under the counter without a prescription, of course, do not have any dangerous side effects, but if you allow a systematic incorrect dosage, then most likely some unpleasant consequences will follow. However, research is ongoing and is mainly focusing on finding some other possible irregularities associated with the labeling of such drugs.